PDF(Pubmed)
Abstract：
Mixed endometrial carcinoma (MEEC) refers to rare endometrial tumours that are composed of two or more distinct histotypes, at least one of which is serous or clear cell. The aim of this study was to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial carcinoma. The medical records of 34 patients diagnosed with MEEC between March 2010 and January 2020 were reviewed retrospectively. Clinicopathological variables and treatment strategies were assessed, and overall survival and disease-free survival rates were evaluated. The histology of endometrioid and serous component was found in 26 (76.5%) patients, followed by serous and clear-cell components (5/34, 14.5%) and mixed endometrioid serous and clear-cell components (3/34, 8.8%). The median age at diagnosis was 70 years (range 52-84), and the median follow-up time was 55 months. The 5-year disease-free survival and the 5-year overall survival were 50.4% and 52.4%, respectively. Advanced disease stage was identified as an independent predictor of inferior disease-free (<0.003) and overall survival (p < 0.001). Except for stage, none of the traditional prognostic factors was associated with disease recurrence or death from disease. MEECs represent rare high-risk endometrial carcinomas with significant diagnostic and treatment challenges. Undoubtedly, the implementation of a molecular analysis can offer further diagnostic and management insights.
摘要：
混合子宫内膜癌（MEEC）是指由两种或两种以上不同组织学组成的罕见子宫内膜肿瘤，其中至少一个是浆液性或透明细胞。这项研究的目的是评估流行病学，混合子宫内膜癌患者的治疗结果和生存率。回顾性分析了2010年3月至2020年1月期间诊断为MEEC的34例患者的病历。评估了临床病理变量和治疗策略，评估总生存率和无病生存率。在26例（76.5%）患者中发现子宫内膜样和浆液性成分的组织学，其次是浆液性和透明细胞成分(5/34,14.5%)和混合的子宫内膜样浆液性和透明细胞成分(3/34,8.8%)。诊断时的中位年龄为70岁（范围52-84），中位随访时间为55个月。5年无病生存率和5年总生存率分别为50.4%和52.4%,分别。晚期疾病分期被确定为低等无病生存率(<0.003)和总生存率(p<0.001)的独立预测因子。除了舞台,传统预后因素均不与疾病复发或疾病死亡相关.MEEC代表罕见的高风险子宫内膜癌，具有重大的诊断和治疗挑战。毫无疑问,分子分析的实施可以提供进一步的诊断和管理见解.
